ArticleJournal of the American Society of Nephrology : JASN2013
Genomic biomarkers correlate with HLA-identical renal transplant tolerance.
Article in Journal of the American Society of Nephrology : JASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Current status of xenotransplantation from an immunobiological standpoint.Clinical transplantation and research · 2025Review
- Foxp3+ regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation.Frontiers in immunology · 2022Review
- Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans.Frontiers in immunology · 2022Review
- Tolerance induction with donor hematopoietic stem cell infusion in kidney transplantation: a single-center experience in China with a 10-year follow-up.Annals of translational medicine · 2020Article
- A Prospective Controlled Trial to Evaluate Safety and Efficacy ofFrontiers in medicine · 2020Article
- Receptor tyrosine kinase MerTK suppresses an allogenic type I IFN response to promote transplant tolerance.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Article
- Contemporary Strategies and Barriers to Transplantation Tolerance.Transplantation · 2018Review
- Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells.Human immunology · 2018Review
- Biomarkers of operational tolerance following kidney transplantation - The immune tolerance network studies of spontaneously tolerant kidney transplant recipients.Human immunology · 2018Review
- Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.Journal of the American Society of Nephrology : JASN · 2018Article
- Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance.Scientific reports · 2018Article
- Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives.Current transplantation reports · 2017Article
- A composite score associated with spontaneous operational tolerance in kidney transplant recipients.Kidney international · 2017Article
- Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation.Frontiers in immunology · 2017Review
- Hematopoietic stem cells and solid organ transplantation.Transplantation reviews (Orlando, Fla.) · 2016Review
- Exome Sequencing and Prediction of Long-Term Kidney Allograft Function.PLoS computational biology · 2016Article
- Immune Tolerance for Autoimmune Disease and Cell Transplantation.Annual review of biomedical engineering · 2016Review
- Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants.Blood · 2016Review
- Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Article
- Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The ability to achieve immunologic tolerance after transplantation is a therapeutic goal. Here, we report interim results from an ongoing trial of tolerance in HLA-identical sibling renal transplantation. The immunosuppressive regimen included alemtuzumab induction, donor hematopoietic stem cells, tacrolimus/mycophenolate immunosuppression converted to sirolimus, and complete drug withdrawal by 24 months post-transplantation. Recipients were considered tolerant if they had normal biopsies and renal function after an additional 12 months without immunosuppression. Of the 20 recipients enrolled, 10 had at least 36 months of follow-up after transplantation. Five of these 10 recipients had immunosuppression successfully withdrawn for 16-36 months (tolerant), 2 had disease recurrence, and 3 had subclinical rejection in protocol biopsies (nontolerant). Microchimerism disappeared after 1 year, and CD4(+)CD25(high)CD127(-)FOXP3(+) regulatory T cells and CD19(+)IgD/M(+)CD27(-) B cells were increased through 5 years post-transplantation in both tolerant and nontolerant recipients. Immune/inflammatory gene expression pathways in the peripheral blood and urine, however, were differentially downregulated between tolerant and nontolerant recipients. In summary, interim results from this trial of tolerance in HLA-identical renal transplantation suggest that predictive genomic biomarkers, but not immunoregulatory phenotyping, may be able to discriminate tolerant from nontolerant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.